Treatment Sequencing of CDK4/6 Inhibitors in Bone-Only Hormone Receptor-Positive Metastatic Breast Cancer: Multi-Center Real-World Data Revealing a Numerical Trend Favoring Later-Line Use
Aug 2026· Cancers· Vol 18· 0 citations· 27 references
Medicine
TL;DR
Real-world findings highlight the need for personalized treatment sequencing in HR+/HER2− MBC patients presenting with bone-only metastasis, and first-line use showed a trend toward longer PFS, while later-line use showed a numerical trend toward longer OS.
Abstract
Simple Summary Cyclin-dependent kinase 4/6 inhibitors (CDK4/6i) combined with endocrine therapy are standard first-line treatments for hormone receptor-positive (HR+), HER2-negative metastatic breast cancer (MBC). However, the optimal sequencing of CDK4/6i for patients presenting with bone-only disease (BoD) remains unclear. In this multi-center retrospective study of 282 patients with baseline BoD, we compared progression-free survival (PFS) and overall survival (OS) between patients receiving CDK4/6i in first-line versus second- or later-line settings. While first-line use showed a trend toward longer PFS, later-line use showed a numerical trend toward longer OS, which lost statistical significance in multivariate analysis. These real-world findings highlight the need for personalized treatment sequencing in HR+/HER2− MBC patients presenting with bone-only metastasis.
Findings support an individualized, risk-adapted sequencing approach in carefully selected patients but do not establish equivalence or justify routine deferral.
Pınar Kubilay Tolunay, Bediz Kurt İnci, B. Karabuğa et al.· Biomedicines· 0 citations
It was unable to demonstrate an association between HER2 status and PFS or OS among patients receiving CDK4/6 inhibitor therapy, and the clinical significance of HER2 status in patients treated with CDK4/6 inhibitors remains unclear.
Esra Aydın, Ç. Öztürk, Oğuzhan Okçu et al.· Medical Journal of Western B...· 0 citations
Effectiveness of first-line ET plus CDK4/6i in patients with HR+/HER2− aBC worsens progressively with decreasing ERα expression, and PgR expression adds further prognostic discrimination, with low ERα and PgR expression identifying a subgroup of patients with particularly poor outcomes.
F. Ligorio, L. Provenzano, R. Caputo et al.· EClinicalMedicine· 0 citations
Objective This study aimed to characterize the tumor response rate, progression-free survival (PFS), and overall survival (OS) among patients with HR-positive, HER2-negative metastatic breast cancer receiving CDK4/6 inhibitors plus endocrine therapy at Ho Chi Minh City Oncology Hospital. Secondary objectives included i...
Thị Phan, Hoang Quy Nguyen· Frontiers in Oncology· 1 citation
Background Real-world data analyses show durable benefits with elacestrant, with or without prior treatment with cyclin-dependent kinase 4/6 inhibitor (CDK4/6i). This cohort focused on patients with ER-positive/HER2-negative estrogen receptor 1 (ESR1)-mutated metastatic breast cancer (mBC) treated with elacestrant afte...
G. Curigliano, M. de Laurentiis, N. Harbeck et al.· ESMO Open· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.